

**To:** Nebraska Medicaid Managed Care Plans  
**From:** Kevin Bagley, Director *KB*  
**Date:** May 12, 2023  
**Re:** Nebraska Medicaid to Cease Coverage of Makena Immediately

---

This health plan advisory is being issued to notify the Heritage Health plans that **effective April 7, 2023**, Nebraska Medicaid will no longer cover Makena (hydroxyprogesterone caproate) and its generic versions.

The Food and Drug Administration (FDA) withdrew approval for Makena (hydroxyprogesterone caproate) and its generic versions on April 6, 2023, which had been approved to reduce the risk of preterm birth. The FDA stated that these drug products have not shown to be effective for the indication in which they were approved and do not have benefits that outweigh their risk to patients.

Compounded hydroxyprogesterone, which is the active ingredient in Makena, has not been reviewed by the FDA for safety and effectiveness in the risk reduction of preterm birth and continues to not be covered by Nebraska Medicaid.

Therefore, Makena and its generic versions will not be covered by Nebraska Medicaid effective April 7, 2023. Prescriptions written on or prior to April 6th, 2023, will be covered.

This health plan advisory supersedes [provider bulletin 18-01](#).

Information on the FDA's decision can be found at the following link: [Makena \(hydroxyprogesterone caproate injection\) Information](#)

Please share this information with your clinical, administrative, and billing staff.

If you have questions regarding this advisory, please call (402) 472-9227 or email [DHHS.MedicaidPharmacyUnit@nebraska.gov](mailto:DHHS.MedicaidPharmacyUnit@nebraska.gov). Health plans should also copy their contract manager.

Health Plan Advisories, such as this one, are posted on the DHHS website at <https://dhhs.ne.gov/pages/Heritage-Health-Plan-Advisories.aspx>. Please subscribe to the page to help you stay up to date about new Health Plan Advisories.